Alemtuzumab
(Lemtrada)
Anti-CD20s (ocrelizumab, ofatumumab, rituximab, ublituximab)
(Ocrevus, Kesimpta, Bonspri, Briumvi, MabThera)
Cladribine
(Mavenclad)
Fumarates (dimethyl fumarate and diroximel fumarate)
(Tecfidera, Vumerity)
Glatiramer acetate (GA)
(Copaxone, Brabio)
HSCT
(Haematopoietic stem cell transplant)
Interferon-beta (IFN-beta)
(Avonex, Betaferon, Betaseron, Extavia, Plegridy, Rebif)
Mitoxantrone
(Novantrone)
Natalizumab
(Tysabri, Tyruko)
Sphingosine 1-phosphate (S1P) modulators (fingolimod, siponimod, ozanimod, ponesimod)
(Gilenya, Mayzent, Zeposia, Ponvory)
Teriflunomide
(Aubagio)
The link below takes you out of the MS-Selfie website to Prof G’s MS-Selfie newsletter and research archive.
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?